SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oncolytics Biotech Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: geoffb_si who wrote (65)4/17/2002 11:00:30 AM
From: geoffb_si  Read Replies (1) of 103
 
Canaccord initiates coverage of Oncolytics with a Speculative Buy Recommendation and 12-month target of $7.

Canaccord daily letter: Speculative buy; target $7

"SPECULATIVE BUY : Oncolytics Biotech Inc. (onc : tse : $3.13 / oncy : nasdaq : US$1.98 : Issued 19.2m)

12-month target price: $7.00
Shameze Rampertab, CA (416) 869-6597

Oncolytics is developing a virus with a simple, targeted mechanism of action against cancer. REOLYSIN is the company?s trademarked reovirus that infects, multiplies in, and destroys mammalian cells with an activated Ras pathway

Validated science in many peer-reviewed journals with compelling clinical data. REOLYSIN is proceeding to a Phase II clinical trial for prostate cancer and a Phase I/II clinical trial for brain cancer

Commercialization strategy is to license REOLYSIN prior to start of Phase III clinical trials. Potential partners include Pfizer, AstraZenecca, Bristol-Myers Squibb, Johnson & Johnson, Schering-Plough, Amgen, and many others in the cancer field

Targeting large cancer markets with unmet needs. Phase I trials have shown no side effects related to REOLYSIN, and has demonstrated preliminary evidence of efficacy

Initiating coverage with a SPECULATIVE BUY recommendation and a 12-month target of $7.00"
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News